Cytomegalovirus Infection
📧 Sign up to get email alerts when something new happens for Cytomegalovirus Infection.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2017-11-08FDA Approved: PREVYMIS — Original Application (Merck Sharp & Dohme LLC)
The FDA approved PREVYMIS (letermovir) for prophylaxis of cytomegalovirus infection in CMV-seropositive adults receiving allogeneic hematopo…
-
CLINICAL_TRIALS trial_result · 2017-10-27Clinical Trial Update: Determining a Viral Load Threshold for Treating Cytomegalovirus (CMV) [Phase 4]
Phase 4 trial completed evaluating whether a viral load threshold can guide treatment for cytomegalovirus infection (viraemia).
-
CLINICAL_TRIALS trial_result · 2017-10-27Clinical Trial Update: CMV Glycoprotein B (gB) Vaccine Long Term Antibody Response
The report provides long-term antibody response data from a cytomegalovirus glycoprotein B vaccine trial conducted by University College Lon…
-
CLINICAL_TRIALS trial_result · 2017-08-15Clinical Trial Update: Comparison Between Two Tacrolimus-based Immunosuppressant Regimens and Induction With Thymoglobulin in Kidney Transplants From Deceased Donors With Expanded Criteria [Phase 4]
A Phase 4 clinical trial comparing two tacrolimus-based immunosuppressant regimens with thymoglobulin induction in deceased-donor expanded-c…
-
CLINICAL_TRIALS trial_result · 2017-08-02Clinical Trial Update: Vaccine Therapy in Healthy Volunteers With or Without Previous Exposure to Cytomegalovirus [Phase 1]
Phase 1 vaccine therapy study in healthy volunteers with or without prior exposure to cytomegalovirus has completed. The trial evaluated saf…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2017-07-06Clinical Trial Update: Impact of the Lack of CMV-Specific CD8+ T Cell Response in CMV-Seropositive Donors in CMV Reactivation After Hematopoietic Stem Cells Transplant in CMV-Seropositive Recipients
This clinical trial update investigates how the absence of CMV-specific CD8+ T cell responses in CMV-seropositive donors may affect CMV reac…
-
CLINICAL_TRIALS trial_result · 2017-07-02Clinical Trial Update: Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney/Pancreas Transplant Recipients [Phase 4]
Phase 4 clinical trial update evaluating valganciclovir to prevent cytomegalovirus infection in kidney and kidney/pancreas transplant recipi…
-
CLINICAL_TRIALS trial_result · 2017-07-02Clinical Trial Update: Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants [Phase 1]
Phase 1 trial evaluating CMV-specific cytotoxic T lymphocytes for CMV prophylaxis in recipients of allogeneic, T-cell depleted stem cell tra…
-
FDA approval · 2017-06-22FDA Approved: VALCYTE — Supplemental Application (H2-Pharma, LLC)
The FDA approved a supplemental application for VALCYTE (valganciclovir) submitted by H2-Pharma, LLC.
-
CLINICAL_TRIALS trial_result · 2017-06-05Clinical Trial Update: Trial of CMV Specific DLIs From 3-6/6 HLA Matched Family Member Following Nonmyeloablative Allo SCT [Phase 1]
Phase 1 trial evaluating CMV-specific donor lymphocyte infusions from 3-6/6 HLA-matched family members after nonmyeloablative allogeneic ste…
-
CLINICAL_TRIALS trial_result · 2017-05-30Clinical Trial Update: Study to Evaluate Safety and Immunogenicity of the GSK Bio CMV Vaccine in CMV-seronegative Healthy Male Adult Subjects [Phase 1]
Phase 1 study evaluating safety and immunogenicity of GlaxoSmithKline's cytomegalovirus vaccine in CMV-seronegative healthy male adults; the…
-
CLINICAL_TRIALS trial_result · 2017-05-09Clinical Trial Update: Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy [Phase 1]
Phase 1 study evaluating a cytomegalovirus vaccine therapy in cancer patients after donor stem cell transplant who have CMV infection refrac…
-
CLINICAL_TRIALS research · 2017-03-07Clinical Trial Update: Diaplacental Transfer of Anti-HCMV- and Anti-VZV-immunoglobulin G (IgG) -Antibodies at Premature and Mature Newborns
The trial investigates placental transfer of anti-CMV IgG and anti-VZV IgG antibodies to premature and full-term newborns. Current status of…
-
FDA approval · 2016-12-06FDA Approved: GANCICLOVIR — Original Application (Endo USA, Inc.)
FDA approves Endo USA's ganciclovir as a generic product under an Original Application, enabling marketing of a generic form of ganciclovir.
-
CLINICAL_TRIALS research · 2016-12-02Clinical Trial Update: The Strategy in the Prevention of Renal Post-transplant Cytomegalovirus Infection Among Chinese Population
The trial update discusses strategies to prevent cytomegalovirus infection in Chinese patients who have undergone renal transplant.
-
CLINICAL_TRIALS research · 2016-11-30Clinical Trial Update: CMV Modulation of the Immune System in ANCA-associated Vasculitis [Phase 2]
This update covers a Phase 2 trial investigating CMV modulation of the immune system in ANCA-associated vasculitis. The current trial status…
-
CLINICAL_TRIALS trial_result · 2016-11-02Clinical Trial Update: A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age [Phase 1]
Phase 1 study assessing the pharmacokinetics and safety of valganciclovir (Valcyte) in pediatric heart transplant recipients under 4 months …
-
CLINICAL_TRIALS trial_result · 2016-10-31Clinical Trial Update: A Study of Valcyte (Valganciclovir) Syrup Formulation in Pediatric Solid Organ Transplant Recipients [Phase 2, Phase 3]
Phase 2/Phase 3 trial assessed valganciclovir syrup in pediatric solid organ transplant recipients for cytomegalovirus infection, with resul…
-
CLINICAL_TRIALS trial_result · 2016-09-14Clinical Trial Update: Cytomegalovirus-Specific Response Measured by QuantiFeron® and Overall Immunologic Response Measured by ImmuKnow® in Lung Transplant Patients CMV-positive
A completed clinical trial in CMV-positive lung transplant patients evaluated CMV-specific immune response using QuantiFeron and overall imm…
-
CLINICAL_TRIALS trial_result · 2016-08-17Clinical Trial Update: Cytomegalovirus (CMV) Infection in Pregnancy
The clinical trial investigating cytomegalovirus infection in pregnancy has completed, per the registry information.
-
CLINICAL_TRIALS trial_result · 2016-08-17Clinical Trial Update: Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence [Phase 4]
A Phase 4 clinical trial update assesses conversion to sirolimus for recurrence of cytomegalovirus infection. The study is sponsored by Hosp…
-
CLINICAL_TRIALS trial_result · 2016-07-26Clinical Trial Update: Prediction of Cytomegalovirus (CMV) Reactivation in Intensive Care Unit (ICU) by Immunological Study
The NCT02843880 clinical trial studying immunological predictors of Cytomegalovirus infection reactivation in ICU patients was terminated.
-
CLINICAL_TRIALS research · 2016-07-21Clinical Trial Update: Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation [Phase 1]
Phase 1 clinical trial evaluating partially HLA-matched third-party antigen-specific T-cells for preventing or treating CMV, EBV, and adenov…
-
FDA approval · 2016-07-18FDA Approved: VALGANCICLOVIR HYDROCHLORIDE FOR ORAL — Original Application (Actavis Pharma, Inc.)
FDA approved an oral valganciclovir hydrochloride product from Actavis Pharma (Original Application) for prevention and treatment of cytomeg…
-
CLINICAL_TRIALS trial_result · 2016-07-14Clinical Trial Update: The Epidemiologic Study of Human Cytomegalovirus（CMV） in Female Students of Xiamen University
A completed epidemiologic study assessing cytomegalovirus infection among female students at Xiamen University.